跳转至内容
Merck
所有图片(4)

主要文件

查看所有文档

R3501

Sigma-Aldrich

利福平

≥95% (HPLC), powder or crystals

别名:

3-(4-甲基-1-哌嗪基亚胺甲基)利福霉素SV, 利米定, 甲哌利福霉素

登录查看公司和协议定价
所有图片(4)

About This Item

经验公式（希尔记法）:
C43H58N4O12
CAS号:
13292-46-1
分子量:
822.94
Beilstein:
5723476
EC號碼:
236-312-0
MDL號碼:
MFCD00151389
分類程式碼代碼:
51283601
PubChem物質ID:
57654590
NACRES:
NA.76

化驗

≥95% (HPLC)

形狀

powder or crystals

顏色

Reddish-brown

pKa 

1.7 (4-hydroxyl group)
7.9 (4-piperazine nitrogen)

pI 

4.84

抗生素活性譜

Gram-negative bacteria
Gram-positive bacteria
mycobacteria
viruses

作用方式

protein synthesis | interferes

儲存溫度

−20°C

SMILES 字串

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O

InChI

1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

InChI 密鑰

JQXXHWHPUNPDRT-WLSIYKJHSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

化学结构:大环内酯物

應用

利福平用于治疗结核病和与结核病相关的分枝杆菌感染。 其广泛应用于自身免疫性胆汁淤积性肝病，原发性胆汁性肝硬化(PBC)的止痒剂。 它已被证明会引起肝炎。

生化／生理作用

作用方式：通过与RNA聚合酶的β-亚基结合抑制RNA合成的起始。
利福平抑制DNA和蛋白质组装成成熟的病毒颗粒。 它通过与RNA聚合酶的亚基结合抑制RNA合成的起始，从而导致细胞死亡。
抑制DNA和蛋白质组装成成熟的病毒颗粒。

其他說明

保持容器密闭在干燥通风处。产品对光和湿度敏感。储存在惰性气体中。干燥处保存

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H302

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 1

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
WXBD4775V
WXBD0542V
WXBC9631V
049M4833V
019M4861V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

M I Prince et al.
Gut, 50(3), 436-439 (2002-02-13)
There is evidence to suggest that rifampicin is an effective second line therapy for controlling pruritus in patients with chronic cholestatic liver disease. It is most widely used as an antipruritic agent in the autoimmune cholestatic liver disease, primary biliary
Samy Figueiredo et al.
Antimicrobial agents and chemotherapy, 53(6), 2657-2659 (2009-03-25)
Two clonally related Acinetobacter baumannii isolates, A1 and A2, were obtained from the same patient. Isolate A2, selected after an imipenem-containing treatment, showed reduced susceptibility to carbapenems. This resistance pattern was related to insertion of the ISAba1 element upstream of
Sandra V Kik et al.
The Journal of infectious diseases, 211 Suppl 2, S58-S66 (2015-03-15)
The potential available market (PAM) for new diagnostics for tuberculosis that meet the specifications of the high-priority target product profiles (TPPs) is currently unknown. We estimated the PAM in 2020 in 4 high-burden countries (South Africa, Brazil, China, and India)
Toril Lindbäck et al.
Veterinary research, 41(1), 8-8 (2009-10-03)
Media-based bacteriological testing will fail to detect non-culturable organisms and the risk of consuming viable but non-culturable (VBNC) Listeria monocytogenes is unknown. We have here studied whether L. monocytogenes obtained from seafoods, processing environment and clinical cases enter the VBNC
Rodney Dawson et al.
Lancet (London, England), 385(9979), 1738-1747 (2015-03-22)
New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门